Zinc oxide nanoparticles, particles smaller than 100 nanometres built from a compound the US Food and Drug Administration already regards as harmless in bulk form, are attracting growing attention as a possible answer to one of oncology’s most stubborn problems: chemotherapy drugs that poison healthy tissue almost as readily as they poison tumours. A review published in July 2026 in Discover Pharmaceutical Sciences by J. A. Badmus and O. D. Afolabi pulls together the evidence that these tiny crystals can trigger selective self-destruction in cancer cells, ferry toxic drugs directly to tumours, and even prime the immune system against malignancy, while candidly cataloguing the obstacles that still stand between laboratory promise and clinical use.
The case for alternatives begins with the shortcomings of existing treatment. The review notes that cancer is the second-leading cause of death globally after cardiovascular disease, with roughly 10 million deaths recorded in 2020 and 10.3 million projected for 2025. Conventional chemotherapeutic agents, whether antimetabolites, biological agents or natural products, frequently fail to deliver a comprehensive anticancer response because tumours develop drug resistance and because the drugs cannot reliably distinguish malignant from normal cells. That lack of selectivity produces systemic toxicity that limits the maximum safe dose. The clinical toll is well documented: chemotherapy-induced nausea and vomiting affect the quality of life of about 80 percent of people living with cancer, gastrointestinal complications such as mucositis and gut inflammation can lead to ulceration, weight loss, anaemia and death, and 47 percent of children treated with carboplatin for solid tumours experienced hypersensitivity reactions in one cited review. Platinum drugs carry risks of cardiovascular disease and nephrotoxicity, and agents including taxanes, bortezomib and vinca alkaloids cause chemotherapy-induced peripheral neuropathy marked by pain, heat allodynia and sensory numbness.
Zinc oxide nanoparticles attack tumours through several converging mechanisms, the most central of which is the generation of reactive oxygen species. Zinc oxide is a semiconductor with a bandgap of 3.37 electronvolts, and at the nanoscale electrons transition to the conduction band even without ultraviolet irradiation. Electrons migrating to the particle surface react with adsorbed and dissolved oxygen to form superoxide radical anions, which proceed through hydroperoxyl radicals to hydrogen peroxide. When these highly reactive species accumulate faster than the cell’s antioxidant defences can neutralise them, the redox balance tips towards oxidative stress and the cell dies. A second mechanism compounds the first: the intracellular release of zinc ions from dissolved nanoparticles pushes zinc concentrations beyond the range that normal enzyme and protein function tolerates, disrupting DNA replication and repair, apoptosis, oxidative phosphorylation and cellular homeostasis. Notably, this dissolution is pH-dependent. Zinc ion release is unfavourable at the neutral pH of blood and extracellular fluid but proceeds rapidly once particles reach the acidic interior of lysosomes, where the pH falls to around 4.7, a chemical quirk that helps explain why the particles preferentially damage cells that have engulfed them.
The selectivity is the headline finding. Several studies reviewed by the authors report that zinc oxide nanoparticles are considerably more toxic to cancer cells than to normal cells, with some indicating toxicity roughly 35 times higher for cancer cells. The review proposes that this differential arises because tumour cells take up nanoparticles more readily, and because the resulting oxidative damage activates the p53 pathway, upregulating the primary cytotoxic response in cancer cells. Downstream of ROS generation and zinc imbalance, the particles suppress anti-apoptotic proteins such as Bcl-2 while inducing pro-apoptotic proteins including Bak and Bax, promote mitochondrial membrane permeabilisation, and trigger caspase cascades that end in nuclear membrane dissolution and programmed cell death. Zinc itself also stabilises the DNA-binding domain of p53, a protein central to apoptosis regulation, adding a further layer to the mechanistic picture.
Beyond direct killing, the review describes zinc oxide nanoparticles as versatile delivery vehicles. Their high surface area-to-volume ratio allows encapsulation of therapeutic agents with efficient release at the target site, minimising cytotoxicity to healthy tissue. Doxorubicin-loaded zinc oxide nanoparticles tested on MCF-7 breast cancer cells showed enhanced cytotoxicity and regulated drug release. Hybrid particles responsive to tumour matrix metalloproteinase 2 and intracellular acidic pH delivered doxorubicin with improved cell penetration, tumour specificity and biocompatibility in multidrug-resistant tumour-bearing mice. The flavonoid taxifolin encapsulated in biodegradable polymer-coated particles induced apoptotic signals and nuclear fragmentation in treated cancer cell lines. The particles have also served as gene delivery vehicles: tetrapod-shaped zinc oxide nanostructures can carry plasmids on their surfaces for targeted gene delivery, an approach first reported by Nie and colleagues in 2006.
Surface engineering multiplies these capabilities. Peptide-functionalised particles targeting placenta-specific protein 1 showed enhanced uptake and selective cytotoxicity in breast cancer cells expressing that protein, compared with non-functionalised particles. Folic acid-functionalised particles preferentially accumulate in folate receptor-positive tumour cells, increasing localised ROS generation while reducing interactions with non-target cells. Particle geometry matters as much as chemistry: porous particles offer larger surface areas for drug loading than rod-like shapes, particles between 10 and 100 nanometres circulate longer and accumulate better at target sites, those under 10 nanometres penetrate tissues deeply but risk damaging healthy barriers such as the blood-brain barrier, particles under about 5 nanometres are filtered by the kidneys, and those above 150 nanometres are captured by the liver, spleen and lungs. Spherical particles between 20 and 150 nanometres tend to show the best tumour accumulation through enhanced permeability and retention.
The immunological dimension is perhaps the most surprising. Zinc oxide nanocomposites exhibit intrinsic immunomodulatory properties and have been investigated as vaccine adjuvants capable of delivering antigens to both endocytic and cytosolic compartments of antigen-presenting cells, enabling simultaneous MHC class I and class II presentation and concurrent CD4-positive and CD8-positive T-cell responses. Structurally engineered nanospheres and nanowires can deliver proteins and nucleic acids into cells even when endocytosis is suppressed, indicating transient membrane penetration. In preclinical cancer models, prophylactic immunisation using antigen-loaded hollow zinc oxide nanoparticles combined with poly(I:C) significantly inhibited tumour growth and lymph node metastasis. The particles also induce pro-inflammatory cytokines including TNF-alpha, IFN-gamma, IL-1 beta and IL-12, supporting Th1-mediated immunity that stimulates natural killer cells and cytotoxic T cells.
The review is equally clear about the caveats, and they are substantial. Most nanotechnology innovations never progress beyond in vivo and in vitro phases to clinical trials. The FDA’s generally-recognised-as-safe designation for zinc oxide applies to micron-scale and larger material; at the nanoscale, new toxicity mechanisms emerge. Zinc oxide nanoparticles have demonstrated significant toxicity to bacteria, mice and human cells. Animal studies cited in the review report DNA damage in peripheral blood and bone marrow cells after oral exposure, oxidative stress within two weeks of subacute exposure, and biochemical abnormalities with histopathological lesions in the kidney, liver and stomach of exposed rats. Male mice showed increased brain, lung and pancreas weights, altered blood enzyme expression, renal disruption, bone marrow oxidative stress and liver DNA degradation. Excess intracellular zinc is linked to neuronal toxicity, and high zinc intake or inhalation has been associated with ataxia and metal fume fever. Prolonged TNF-alpha exposure harms host cells. Batch-to-batch variation in surface chemistry, size distribution and stability further complicates interpretation, and large-scale synthesis with predictable performance remains impractical for most formulations.
The authors’ recommendations read as a research roadmap rather than a clinical forecast. They call for design rules linking particle size, shape and surface chemistry to biodistribution and tumour targeting; standardised toxicity testing using mechanistic endpoints such as ROS production, DNA damage, inflammation and immune response; evaluation of long-term in vivo behaviour including biodegradation, ion release and clearance; assessment of combination therapies with chemotherapy, radiotherapy and immunotherapy in clinically relevant tumour models; and standardised protocols for synthesis, characterisation and safety assessment. Mitigation strategies already under study include green synthesis using plant extracts instead of chemical agents, polymer coatings that reduce aggregation and toxicity, iron doping or surface capping to moderate dissolution rates, and chitosan coatings to improve biocompatibility. What the evidence supports today is a body of preclinical work, largely in cell lines and animal models, showing that zinc oxide nanoparticles can kill cancer cells selectively, deliver drugs and genes to tumours, and modulate immune responses, alongside a parallel body of work showing that the same properties can damage healthy tissue. Whether that balance can be engineered in favour of the patient remains the defining question for this field.
Subject of Research: A review of zinc oxide nanoparticles as anticancer and drug delivery agents
Article Title: Zinc oxide nanoparticles as a plausible alternative to overcome contemporary chemotherapeutic challenges
Article References: Badmus, J. A., & Afolabi, O. D. (2026). Zinc oxide nanoparticles as a plausible alternative to overcome contemporary chemotherapeutic challenges. Discover Pharmaceutical Sciences, 2(1), Article 15. https://doi.org/10.1007/s44395-026-00051-7
Image Credits: AI Generated
DOI: 10.1007/s44395-026-00051-7
Keywords: zinc oxide nanoparticles, cancer therapy, chemotherapy side effects, reactive oxygen species, targeted drug delivery, nanotechnology, apoptosis, anti-angiogenesis, cancer immunotherapy, nanotoxicology, green synthesis, preclinical research
News Source: Nathaniel Bowman. (October 29, 2026). Zinc Oxide Nanoparticles Emerge as a Selective Cancer-Killing Alternative to Chemotherapy. Scienmag.
